Immuneering’s IMM-6-415 receives FDA clearance for phase I/IIa trial in solid tumors with RAF or RAS mutations
Dec. 13, 2023
Immuneering Corp. has obtained FDA clearance of its IND application for IMM-6-415, an oral, twice-daily small molecule in development for the treatment of advanced RAF or RAS mutant solid tumors.
